Search clinical trials for: Radium-223 (Xofigo, BAY88-8223)

Total 213 results

Sidney Kimmel Comprehensive Cancer Center at Johns...
Bayer; Dendreon

Completed

Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC

Prostate Cancer

United States
Bayer

Completed

A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223 (BELFIGO)

Prostatic Neoplasms, Castration-Resistant

Belgium
Bayer

Completed

Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the Body (REACTIVATE)

Prostate Cancer

Canada
Bayer

Completed

EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo) (EPIX)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States
Bayer

Completed

Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis

Prostatic Neoplasms

China, Singapore, Taiwan, Korea, Republic of
Bayer

Completed

A Drug Utilization Study of Radium-223 in Sweden

Neoplasms

Sweden
Bayer

Active, not recruiting

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer (REASSURE)

Metastatic Castration-resistant Prostate Cancer

United States, Austria, Czechia, Israel, Italy, Germany, United Kingdom, France, Mexico, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Denmark, Sweden, Argentina, Portugal
Bayer

Completed

Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population

Prostate Cancer

United States
Bayer

Completed

Treatment Patterns in Metastatic Prostate Cancer

Prostatic Neoplasm

United States
Bayer

Completed

A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety (QOLRAD)

Prostate Cancer

Colombia
Bayer

Completed

Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany (URANIS)

Prostatic Neoplasms, Castration-Resistant

Germany
Bayer

Completed

Treatment Satisfaction With Ra-223 in Japan

Prostatic Neoplasms

Japan
Bayer

Terminated

A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels (CREDIT)

Bone Metastases | Metastatic Castration-resistant Prostate Cancer

China
Bayer

Completed

Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases (PARABO)

Castration-Resistant Prostatic Cancer

Germany
Bayer

Completed

Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases

Prostatic Neoplasms

United States, Israel, Spain, Italy, Sweden, Norway, Finland
Bayer

Completed

Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients

Prostatic Neoplasms

Japan
Bayer

Completed

A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before (DIRECT)

Bone Metastatic Castration-resistant Prostate Cancer

Germany, Netherlands, Denmark
Bayer

Completed

Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer ) (Navigant)

Prostatic Neoplasms, Castration-Resistant

United States
Bayer

Active, not recruiting

Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone (RAPIT)

Castration-resistant Prostate Cancer

Taiwan
Bayer

Completed

Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone

Prostatic Neoplasms

United States, Canada, Taiwan, Spain, Australia, Czechia, Germany, Israel, Korea, Republic of, France, Brazil, Chile, Italy, Sweden, United Kingdom
Bayer

Completed

PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn (PRECISE)

Metastatic Castration-Resistant Prostate Cancer

Sweden
Bayer

Withdrawn

Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study

Prostatic Neoplasms, Castration-Resistant
Bayer

Completed

Japanese BAY88-8223 Monotherapy Phase II Study

Prostatic Neoplasms

Japan
Bayer

Active, not recruiting

A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones

Bone Metastatic Castration-resistant Prostate Cancer

France, Lithuania, Israel, Italy, United Kingdom, Austria
Bayer

Completed

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo). (PHENIX)

Metastatic Castration-resistant Prostate Cancer (mCRPC)

United States
University of Southern California
National Cancer Institute (NCI)

Active, not recruiting

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer | Prostate Carcinoma Metastatic in the Bone

United States
University of Washington
Bayer

Recruiting

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8

United States
Bayer

Completed

PK in Pts With HRPC & Skeletal Metastes

Prostatic Neoplasms

United Kingdom
Bayer

Terminated

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

Breast Neoplasms

Spain, Canada, United States, Finland, Austria, Singapore, Czechia, Israel, Korea, Republic of, Netherlands, Taiwan, United Kingdom, Poland, Germany, Hong Kong, Denmark, Switzerland, Ireland, France, Norway
Bayer

No longer available

Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Prostatic Neoplasms

United States
Bayer

Completed

A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases (ALSYMPCA)

Bone Metastases | Hormone Refractory Prostate Cancer

Italy, Spain, Hong Kong, Canada, United Kingdom, France, Australia, United States, Germany, Brazil, Israel, Netherlands, Norway, Belgium, Sweden, Czech Republic, Poland, Singapore, Slovakia
Bayer

Completed

Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton

Prostate Cancer | Pharmacokinetics | Metastases

United States
Bayer

Completed

BAY88-8223, Does Response Study in HRPC Patients

Bone Metastases | Hormone Refractory Prostate Cancer
Bayer

Completed

Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases

Neoplasm Metastasis

Sweden, Norway
Bayer

Completed

A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer

Neoplasm Metastasis | Prostate Cancer

Sweden, United Kingdom
Bayer

Completed

BAY88-8223, Dose Finding Study in Patients With HRPC

Neoplasm Metastasis | Prostate Cancer

United Kingdom
Bayer

Completed

Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Prostatic Neoplasms

Belgium, Spain, Canada, France, Switzerland, Germany, United Kingdom, Denmark, Russian Federation, Sweden, Israel, Italy, Netherlands, Norway, Czech Republic, Finland, Poland, Ireland, Mexico
Bayer

Active, not recruiting

Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases

Prostatic Neoplasms, Castration-Resistant

Japan
Bayer

Completed

BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease

Breast Cancer | Bone Metastases

Belgium, United Kingdom, Norway
Bayer

Recruiting

Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Czechia, France, Hungary, Italy, Poland, Spain, Taiwan, United Kingdom, Korea, Republic of, Singapore, Hong Kong, Australia, Finland, Germany, Israel, Lithuania, Russian Federation, Turkey, Austria
Bayer
Merck Sharp & Dohme LLC

Terminated

Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

Carcinoma, Non-Small-Cell Lung

Spain, Belgium, Netherlands, United States
Bayer

Completed

A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

Bone Metastases | Castration-Resistant Prostate Cancer

United States, France
Radboud University Medical Center
Bayer

Completed

Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223

Bone Metastases | Castrate Resistant Prostate Cancer

Netherlands
Bayer

Completed

Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions

Neoplasms | Bone Diseases

Israel, United Kingdom, Finland
Sidney Kimmel Cancer Center at Thomas Jefferson...
Bayer; Janssen, LP; Prostate Cancer Clinical Trials Consortium

Completed

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

Stage IV Prostate Adenocarcinoma | Hormone-refractory Prostate Cancer | Prostate Carcinoma Metastatic to the Bone

United States
GenesisCare USA
Bayer

Withdrawn

Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC (CARE)

Metastatic Prostate Cancer
M.D. Anderson Cancer Center
Bayer; Prostate Cancer Foundation

Completed

Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases

Prostate Cancer

United States
University of California, San Francisco
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

Not yet recruiting

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

Castration-Resistant Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IVB Prostate Cancer AJCC v8

United States
Canadian Urology Research Consortium
Bayer

Withdrawn

Radium 223 Following Intermittent ADT (RAND)

Prostate Cancer

Canada
Angela Taber MD
Bayer; The Miriam Hospital; Rhode Island Hospital

Completed

BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases

Non Small Cell Lung Cancer With Bone Metastatses

United States

3

Subscribe